Femtobiomed Inc. Logo

Femtobiomed Inc.

Develops a non-viral intracellular delivery platform for cell and gene therapy.

327610 | KO

Overview

Corporate Details

ISIN(s):
KR7327610002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 700D동 510호(야탑동, 분당테크노파크), 성남시

Description

Femtobiomed Inc. is a cell engineering company that develops technologies for the cell and gene therapy industry. The company's core offering is the CellShot® platform, a proprietary, non-viral intracellular delivery system. This platform utilizes a patented technology known as 'Partitioned Flow Transfection,' which functions as a three-dimensional nanoinjection system for the direct, cargo-free delivery of biomolecules into individual cells. The technology is designed to support the discovery and development of advanced therapeutics, including anti-cancer treatments, for the healthcare and research sectors. Femtobiomed aims to pioneer non-viral cell engineering to accelerate the creation of novel cell therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-19 00:00
주식등의대량보유상황보고서(일반)
Korean 137.0 KB
2025-06-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-06-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.5 KB
2025-06-13 00:00
기업설명회(IR)개최결과
Korean 6.7 KB
2025-06-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-09 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 53.3 KB
2025-06-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.7 KB
2025-04-28 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 31.1 KB
2025-04-28 00:00
기타주요경영사항(자율공시) (제1회차 전환사채권 발행결정 철회)
Korean 6.4 KB
2025-04-02 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-03-31 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-03-31 00:00
주식등의대량보유상황보고서(일반)
Korean 108.8 KB
2025-03-26 00:00
정기주주총회결과
Korean 19.3 KB
2025-03-24 00:00
[기재정정]주주총회소집공고
Korean 81.6 KB
2025-03-20 00:00
주요사항보고서(전환사채권발행결정)
Korean 56.8 KB

Automate Your Workflow. Get a real-time feed of all Femtobiomed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Femtobiomed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Femtobiomed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ceres Power Holdings PLC Logo
A developer of solid oxide technology for clean power and green hydrogen production.
United Kingdom
CWR
Certara, Inc. Logo
Accelerates drug development using biosimulation software, technology, and services.
United States of America
CERT
CervoMed Inc. Logo
A clinical-stage biotech developing treatments for age-related neurologic disorders.
United States of America
CRVO
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and provides CDMO and bio-banking services.
South Korea
085660
CHAMPIONS ONCOLOGY, INC. Logo
A CRO providing end-to-end solutions to accelerate oncology drug development.
United States of America
CSBR
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Logo
A contract research organization supporting drug discovery and development.
United States of America
CRL
Chiome Bioscience Inc. Logo
Clinical-stage biotech company developing antibody-based therapeutics.
Japan
4583
Chordate Medical Holding AB Logo
Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.
Sweden
CMH
Chordia Therapeutics,Inc Logo
Clinical-stage biotech developing novel cancer therapies targeting RNA deregulation.
Japan
190A
Cibus, Inc. Logo
Develops and licenses plant traits using non-GMO precision gene-editing technology.
United States of America
CBUS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.